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Abstract. Background: A Disintegrin And Metalloprotease
domain 29 (ADAM29) is involved in many important
physiological processes. Recent studies have demonstrated
that ADAM29 is a susceptibility locus showing traits as a
risk factor for breast cancer under genome-wide
significance, however, the clinical relevance and cellular
function of ADAM29 in breast cancer have not been
reported. Materials and Methods: In this study, we assessed
the expression levels of ADAM29 in a cohort of human breast
cancer specimens. We also used MDA-MB-231 cells with
differing ADAM29 expression and assessed the influence of
ADAM29 and its mutations on the MDA-MB-231 cell line.
Results: Increased transcript expression of ADAM29 was
observed in breast cancer tissues compared to normal ones.
The expression of ADAM29 and its mutations in different
domains significantly influenced proliferation, migration and
invasion of breast cancer cells in vitro. Conclusion: ADAM29
may represent a prognostic factor in human breast cancer,
as well as a novel molecular candidate to be used as a
therapeutic target.
Breast cancer is the most common cancer among females
according to 2012 GLOBOCAN statistics, nearly 1.7 million
women were diagnosed with breast cancer with 522,000
related deaths (1). If breast cancer is detected at stage IIIB
or later, the 5-year survival rate may be significant reduced
than the one if detected at earlier stages (2). Therefore, it is
of high scientific importance to discover an ideal molecular
target for diagnosis and treatment of breast cancer.
ADAMs (a disintegrin and metalloprotease) are a family
of integral membrane and secreted glycoproteins mediating
cell-cell and cell-matrix interaction. They have functional
similarity to MMPs in their zinc-binding metalloprotease
domains, and are also referred to as the disintegrin, cysteine-
rich (MDC) family. They are membrane-anchored
glycoproteins containing both protease and adhesion
domains that have several biological functions, like
encompassing cell adhesion through their cysteine-rich
domains that bind to syndecans and fibronectin (3, 4), cell
fusion and signaling (5, 6). Studies have shown that several
members of the ADAM family are highly expressed in a
variety of human carcinomas, likely contributing to tumor
development and/or progression (7-9). 
A novel human ADAM gene ADAM29, located in human
chromosome 4q34 (10), was suggested to be involved in
cancer development and progression. High ADAM29
expression was predictive of a long treatment-free interval in
Binet stage A B-cell chronic lymphocytic leukemia patients
(11). ADAM29 up-regulation increased proliferation of
gastric carcinoma MKN45 cells, whereas cell-cell
aggregation was decreased (12). Recently, several genome-
wide association studies have shown that ADAM29 is a
susceptibility locus and a risk factor for breast cancer at the
genome-wide significance level (13-15). Although ADAM29
has been considered as playing important roles in different
kinds of cancers, the precise role and mechanism of
ADAM29 in breast cancer remain largely unknown. 
Moreover, the presence of distinct somatic mutations in
several members of the ADAM family suggests a direct
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involvement of these genes in cancer genesis. According to
the existing research, ADAM29 was found with a highest rate
of mutation in malignant tumors including melanoma (16),
esophageal cancer (17), colorectal cancer (18) and breast
cancer (14). 
Functional analysis of the frequently mutated ADAM29 in
melanoma demonstrated that the mutations affected adhesion
of melanoma cells to specific extracellular matrix proteins
and in some cases increased their migration ability (16).
However, the effects of ADAM29 mutations in breast cancer
have not been reported. 
In this article, the clinical relevance of ADAM29 expression
was analyzed in a cohort of breast cancer samples. The effects
of wild-type and point-mutations (P31L, H63Y and L225I) of
ADAM29 on cell proliferation, migration and invasion of
MDA-MB-231 were first examined in vitro. 
Materials and Methods
Human breast specimens. A total of 142 breast samples were
obtained from breast cancer patients (31 were background normal
breast tissue and 111 were breast cancer tissue). These tissues were
collected immediately after mastectomy, and snap-frozen in liquid
nitrogen, with the approval of the local research ethical committee.
Adjacent background normal mammary tissues were obtained from
the dissected mammary tissues. The pathologist verified normal
background and cancer specimens, and it was confirmed that the
background samples were free from tumor deposits. The median
follow-up for the cohort was 120 months (June 2004). The relevant
information is provided in Table I.
RNA preparation and real-time quantitative polymerase chain
reaction (QPCR). Real time quantitative PCR (QPCR) was
performed on the Icycler IQ5 system (Bio-Rad, Hammel Hemstead,
UK) to quantify the level of ADAM29 transcripts in the breast
cancer specimens (shown as copies/μl from internal standard). The
QPCR technique utilized the Amplifluor system™ (Intergen Inc.,
England, UK) and QPCR master mix (BioRad, Camberley, UK).
Pairs of primers were designed using Beacon Design software
(PREMIER Biosoft, Palo Alto, CA, USA): ADAM29 QPCR primers
as follow: sense: 5’-GAATC CCTGG TTTCC CTCAG-3’;
antisense: 5’-ACTGAACCTGACCGTACAGTTTCTCCTCACTG
TCCAT CTTG-3’. Z-sequence on Q-PCR primers is 5’ACTGAACC
TGACCGTACA’3, which is complementary to the universal Z probe
(TCS Biologicals Ltd., Oxford, UK). Real-time QPCR conditions
were 95˚C for 15 min, followed by 60 cycles at 95˚C for 20 s, 55˚C
for 30 s and 72˚C for 20 s. 
Immunohistochemical staining of breast specimens. The frozen
paired tissues were cut into 7-μm sections, and immunohisto-
chemically stained as described previously (19). 
ADAM29 monoclonal antibody was from Abnova (Taiwan,
China). A peroxidase conjugated goat anti-mouse immunoglobulin
IgG was obtained from ZSGB Biotechnology (Beijing, China). The
diaminobenzidine (DAB) chromagen (Cell Signal Technology,
Danvers, MA, USA) was used for the colouration. Finally, the
sections were observed under the microscope (BX43, Olympus,
Tokyo, Japan). Staining was independently assessed by the authors. 
Cell line and culture. The breast cancer cell line, MDA-MB-231
was purchased from the Cell Culture Center (cell resource center,
shanghai institute for biological sciences, Chinese Academy of
Sciences, Shanghai, China), and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum,
penicillin and streptomycin (Gibco BRC, Paisley, Scotland) in an
incubator at 37˚C, 5% CO2, and 95% humidity.
Preparation of plasmids. ADAM29 cDNA were cloned into GV141
vector by Genechemcompany (Shanghai, China) to obtain the Flag-
ADAM29 expression construct. The constructs of ADAM29 mutants
P31L, H63Y, L225I were generated based on the wide-type plasmid
using phusion PCR for site-directed mutagenesis by Genechem
company (Shanghai, China). The shRNA targeted to ADAM29 and
the control shRNA plasmids were constructed by Genechem





Cell transfection. Sub-confluent cells were transfected with various
constructs by using lipofectamine reagent according to
manufacturer’s instructions (Invitrogen, Camarillo, CA, USA).
MDA-MD-231 cells were selected in the culture medium with
1,200 μg/ml G418 or 0.5 μg/ml puromycin respectively for further
21 days to generate stable ADAM29-expressing cells or ADAM29
knockdown cells. ADAM29 expression was verified using western
blotting.
Cell proliferation assay. Cell viability was evaluated by a non-
radioactive cell counting kit (CCK-8, Dojindo, Kamimashiki-gun,
Kumamoto, Japan) assay that was performed according to
manufacturer’s instructions. Cells were seeded in a 96-well plate at
3×103 cells per well, and after every 24 h, add CCK-8 reagent to
each well and the plates were incubated for an additional 1 h at
37˚C. Cell viability was measured as the absorbance at 450 nm
with an Elx800™ spectrophotometer (BioTek, Winooski, VT,
USA).
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Table I. Patients’ characteristics.
Clinical data Grouping N
Tissue sample Normal 31
Tumor 111
Tumor grade 1 20
2 37
3 52




Clinical outcome Disease-free 80
With metastasis 7
With local recurrence 5
Died of breast cancer 13
Wound-healing assay. Migratory property of the breast cancer cells
was assessed by wound-healing assay, as described previously (20).
Images of the wound were recorded under a phase contrast
microscope at different time (0 h, 6 h, 12 h, 24 h). Wound
closure/cell migration was evaluated with Image-Pro plus.
In vitro Matrigel invasion assay. 2×104 cells in 200 μl of culture
medium with 1% FBS were added to the upper chamber of
transwell chamber (Corning, ME, USA) containing 8.0 μm pores,
while the lower chamber was filled with 600 μl of culture medium
with 20% FBS. After incubated for 48h, the cells were fixed,
stained, and quantified as described before (21).
Statistical analysis. The results of in vitro assays were assessed
using non-paired (two-sided) Student’s t-test, one-way ANOVA test
with SPSS 19.0 software. ADAM29 mRNA values obtained in the
QPCR study are given as mean transcript copy number per 50 ng of
RNA±SD. The relationship between the expression of ADAM29 and
tumor grade, TNM staging and survival status were respectively
analyzed using Mann–Whitney U-test (Table II). A p-value <0.05
was defined as statistically significant.
Results
Expression of ADAM29 in the clinical breast cohort.
ADAM29 expressed in the cytoplasm of both normal breast
epithelial cells and cancerous cells in the invasive ductal
carcinoma (Figure 1). The staining appeared to be weaker
from the normal breast cells compared with breast cancer
cells (Figure 1). ADAM29 transcript levels were also
examined in the breast cohort using quantitative PCR. An
increased level of ADAM29 expression was revealed in breast
tumors, compared with normal tissues (Table II). The
expression levels of ADAM29 were found to be elevated in
the moderately differentiated (grade 2) and poorly
differentiated (grade 3) tumors when compared to well
differentiated (grade 1) tumors. A trend was also observed
that higher levels of ADAM29 transcripts tended to be more
frequently observed in the local advanced tumors (TNM II
and III) tumour. Further analysis of ADAM29 transcript
levels against the clinical aspects demonstrated that
increased ADAM29 expression was correlated with poor
disease prognosis (included with metastasis, with local
recurrence and died of breast cancer) over the 10 year
follow-up period in comparison with those who remained
disease-free. These results suggested ADAM29 expression
level is associated with the poorer-outcome patients of breast
cancer, though these differences were not statistically
significant.
ADAM29 expression affected malignant phenotypes of MDA-
MB-231 cells. ADAM29 protein was strongly present in the
ADAM29-overexpressing cells (Figure 2A) and reduced in the
ADAM29-knockdown cells (Figure 2B). Compared to control
cells, cell proliferation were significantly promoted from the
second day, and by up to 54% in cells overexpressing ADAM29
on day 4 (Figure 2C), while cell proliferation was reduced to
68% on day 4 in MDA-MD-231 ADAM29-kd cells (Figure
2D). Cell migration and invasion of ADAM29 overexpression
cells were also increased up to 94% and 20% at 24 h and 48 h,
respectively (Figure 2E and G). The knockdown of ADAM29
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Table II. Correlation of ADAM29 mRNA expression and clinical parameters.
Category No. Median IQR p-Value
T/N
Normal 31 16 <0.000001-2608
Tumor 111 390 <0.000001-7863 0.22
Tumor grade
1 20 26 <0.000001-2695
2 37 190 <0.000001-41920 0.73
3 52 1365 3-7808 0.10
23 89 619 <0.000001-15645 0.23
TNM staging
Ⅰ 59 97 <0.000001-4419
Ⅱ 35 1296 2-30063 0.17
Ⅲ 7 6794 468-30542 0.11
II&III&Ⅳ 46 1178 6-28493 0.08
Clinical outcome
Disease-free 80 404 <0.000001-11190
With metastasis 7 1060 318-5005 0.62
With local recurrence 5 <0.000001 <0.000001-34.5 0.30
Died of breast cancer 13 1691 60-50553 0.31
Met+dead 20 1375 169-24921 0.29
Met+rec+dead 25 724 <0.000001-6531 0.96
significantly reduced the migratory and invasive nature of
breast cancer cells (Figure 2F and H). These results strongly
suggested that ADAM29 play an important role in the
regulation of malignant phenotypes of MDA-MB-231 cells by
promoting cell proliferation, migration and invasion.
Effects of ADAM29 mutation on cell growth, migration and
invasion. ADAM29 was reported to be frequently mutated in
melanoma (16). Most mutations were found located in the
pro-protein and reprolysin domain of ADAM29 proteins. To
further examine if these mutations could regulate the
oncogenic function of ADAM29, two missense mutations
P31L and H63Y located within proprotein of ADAM29 and
mutation L225I within reprolysin of ADAM29 were
introduced into MDA-MB-231 cells respectively. As
demonstrated by western Blotting, these mutants were
expressed at similar levels to wild-type ADAM29 (ADAM29-
ex) (Figure 3A). We then explored their effects on the
malignant phenotypes of cancer cells. As shown in Figure
3B, each of the ADAM29 mutations significantly increased
the cell proliferation. ADAM29 P31L and H63Y mutations
significantly increased the cell proliferation to a similar level
that was seen in wild-type ADAM29 overexpression cells.
While the growth rate of cells overexpressing ADAM29
L225I was 17.2% more than those expressing wild-type
ADAM29 on day 4, which suggested the stronger capability
of promoting cell growth of ADAM29 L225I. As well as the
effects on cell growth, P31L, H63Yand L225I mutations of
ADAM29 increased the capability of cell invasion compared
with wild-type ADAM29 (Figure 3C). Furthermore, three of
the ADAM29 mutants showed the similar effect with the
wild-type protein on cell invasion. In contrast, the various
ADAM29 mutants reduced cell migration compared to wild-
type ADAM29, though the more migratory rate was observed
in the mutation cells than in vehicle control cells (Figure
3D). These results strongly suggested ADAM29 and the
mutants participated in the regulation of growth, migration
and invasion of breast cancer cells.
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Figure 1. Expression of ADAM29 in normal breast tissue and breast cancer tissue. Different levels of ADAM29 were detected in the cytoplasm of both
normal breast cells and cancerous cells. Immunohistochemical staining revealed the increased staining of ADAM29 in breast cancer sections
compared with normal tissue.
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Figure 2. ADAM29 promotes cell growth, migration and invasion in vitro. A, B: Overexpression and knockdown of ADAM29 at the protein level in
breast cancer cell MDA-MB-231 were verified using western blot. C: ADAM29 overexpression promoted MDA-MB-231 cells growth over the
experimental time points compared to control plasmid cells. D: Reduced growth rate of cells was seen in ADAM29 knockdown MDA-MB-231 cells.
E, G: Significant increase in cell migration and cell invasion were seen in ADAM29 overexpressing cells. F, H: A reduced migration and cell invasion
was seen in the MDA-MB-231 ADAM29 knockdown cells. *p<0.05, **p<0.01.
Discussion
Recently, the ADAM family was reported to have
association with the progression of human breast cancer
(22-25). In the current study, we reported that increased
transcript expression of ADAM29 was observed in the
breast cancer tissue sections compared to normal tissues.
The follow-up analysis presented that ADAM29 expression
was increased in poorer-outcome patients with breast
cancer. The results suggested an oncogenic role of
ADAM29 in breast cancer, which was further confirmed by
the in vitro function assays. Overexpression of ADAM29
promoted cell proliferation of MDA-MD-231 cells, and
knockdown of ADAM29 showed the opposite effect on cell
proliferation. It was also observed that knockdown
ADAM29 reduced the ability of migration and invasion in
breast cancer cell lines. On the contrary, higher expression
of ADAM29 sharply promoted migration and invasion
compared with the control cells. The results of both gain-
of-function and loss-of-function studies indicated that
ADAM29 acted as an oncogene in breast tumor cells.
A systematic mutational analysis of the ADAMs gene
family in human cancers discovered two frequently mutated
ADAM genes, ADAM7 and ADAM29. 1,465 mutations in
ADAM29 identified from 727 donors were reported by 40
projects (https://dcc.icgc.org/genes/ENSG00000168594).
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Figure 3. Effects of mutant ADAM29 on cell growth, migration and invasion. A: The wild-type (ADAM29-ex) and mutants of ADAM29 (P31L, H63Y,
L225I) were overexpressed in MDA-MB-231 cells. B: ADAM29 wild-type and mutants promoted the growth of MDA-MB-231 cells at the same level.
C: Overexpression of ADAM29 mutations increased the invasive capability of MDA-MB-231 cells. D: The ADAM29 mutants reduced cell migration
compared with wild-type ADAM29. *p<0.05, **p<0.01.
Most mutations located in the pro-protein and reprolysin
domains of ADAM29 protein. The expression of the
ADAM29 mutants in melanoma substantially increased the
melanoma cell adhesion to collagen I and IV compared to
cells expressing wild-type ADAM29 (16). However, the
effects of ADAM29 mutations in breast cancer have not
been reported to date. In order to study the effects of
ADAM29 mutations on cell function, three mutants (P31L,
H63Y andL225I) were constructed. P31L and H63Y
located in the pro-protein domain of ADAM29, while L225I
located within the reprolysin domain. Results showed that
three mutations of ADAM29 increased the invasive
capability of MDA-MB-231 cells that may play pivotal role
in the process of tumor progression and metastasis. In
addition, the mutation in the reprolysin domain of ADAM29
enhanced the oncogenic role of wild type ADAM29 on
promoting proliferation of MDA-MD-231 cells. In contrast,
the ADAM29 mutants reduced cell migration compared
with wild-type ADAM29.
The development of normal breast tissue into breast cancer
should undergo the stage of atypical hyperplasia, carcinoma
in situ, and invasive cancer, then metastases occur. Tumor
cells should firstly obtain a strong ability of proliferation and
invasion at the early stage of tumor development and
progression. Migration is the ability of cells to move to
another place, or movement in the blood and lymph vessel.
The three mutants of ADAM29 in our study increased the
invasion ability of breast cancer cells, and L225I allow the
breast cancer cells to obtain a stronger proliferative ability.
These results suggested that ADAM29 mutants could play an
important role mainly in the development of breast cancer at
the start and early stage.
In conclusion, our data showed higher levels of ADAM29
were apparent in patients with poorer outcome. The results
of both gain-of-function and loss-of-function studies
indicate that ADAM29 may act as an oncogene in tumor
cells. Mutations in different domain of ADAM29 affected
proliferation, migration and invasion of breast cancer. All
these findings could provide significant clinical
applications, including the use of ADAM29 as a molecular
marker in breast cancer diagnosis, as well as an indicator
for prognosis. In addition, ADAM29 may present a novel
molecular candidate for therapeutic target in breast cancer,
that requires further study to better understand the
mechanism of action.
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